BEIJING: Ustar, a Chinese point of care (POC) startup that designs molecular diagnostic systems, has raised about ¥300 million (US$2.6 million) in a Series E+ funding round. The investment was led by CPE Yuanfeng. Current Ustar shareholder Oriental Fortune Capital also made an additional investment. Ustar plans to use part of the funds raised to make its flagship high-throughput, fully automatic nucleic acid amplification test system more efficient. The rest will be used to expand the types of testing, to mass-produce polymerase chain reaction (PCR) testing systems for household use, and to develop a next-generation testing platform. Since its establishment,…